

CORRECTION

Open Access



# Correction: Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

Wangbin Ma<sup>1,2,3†</sup>, Qiao Shi<sup>1,2,3†</sup>, Lilong Zhang<sup>1,2,3</sup>, Zhendong Qiu<sup>1,2,3</sup>, Tianrui Kuang<sup>1,2,3</sup>, Kailiang Zhao<sup>1,3\*</sup> and Weixing Wang<sup>1,2,3\*</sup>

**Correction:** BMC Cancer 24, 830 (2024)  
<https://doi.org/10.1186/s12885-024-12579-x>

Following publication of the original article [1], a typesetting error was reported. The initials of author Kailiang Zhao (ZK) were erroneously added to the author group. This has been removed in this correction article.

Further to this, the authors reported an error in Table 1, whereby the last row in the table was omitted.

<sup>†</sup>Wangbin Ma and Qiao Shi contributed equally to this work and are joint first authors.

The original article can be found online at <https://doi.org/10.1186/s12885-024-12579-x>.

\*Correspondence:

Kailiang Zhao  
zhaokl1983@whu.edu.cn  
Weixing Wang  
wangwx@whu.edu.cn

<sup>1</sup> Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan, China

<sup>2</sup> Hubei Key Laboratory of Digestive System Disease, Wuhan, China

<sup>3</sup> Laboratory of General Surgery, Renmin Hospital of Wuhan University, Wuhan, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

The incorrect Table 1:

**Table 1** Main characteristics of the studies included

Study	Study design	Study region	Study period	Sample size	Age	Male/female	Site	Treatment line	Treatment	Follow-up (months)	Body Composition Variables	Outcomes
Aslan et al. 2022 [19]	R	Turkey	10/2010-10/2021	52	30/22 <sup>d</sup>	38/14	RCC	II	Nivolumab	11.4 (0.7-63) <sup>a</sup>	SAI	OS, PFS
Fukata et al. 2022 [20]	R	Japan	02/2018-03/2021,	44	70 (54-80) <sup>a</sup>	30/14	UC	II	Pembrolizumab	13.2(1-40.8) <sup>a</sup>	SMI	PFS
Ged et al. 2022 [21]	R	USA	07/2011-04/2020	205	63 (40-90) <sup>a</sup>	152/53	RCC	VII	ICI	31.2 (1-77.8) <sup>a</sup>	SMI, VAI, SAI	OS
Herrmann et al. 2022 [22]	R	France	2016-2020	46	66 (37-86) <sup>a</sup>	31/13	RCC	II	Nivolumab	16 <sup>c</sup>	SMI	OS
Ueki et al. 2022 [23]	R	Japan	12/2016-10/2020	96	65/31 <sup>e</sup>	71/25	RCC	II	Nivolumab	9.7 (0.3-48.4) <sup>a</sup>	PMI, SMI	OS, PFS
Martini et al. 2021(RCC) [24]	R	USA	2015-2020	79	61.0 <sup>f</sup>	58/21	RCC	VII	ICI	-	SMI, VAI, SAI, IAI	OS, PFS
Martini et al. 2021(UC) [25]	R	USA	2015-2020	70	69.5 <sup>f</sup>	49/21	UC	VII	ICI	20.1 <sup>c</sup>	SMI, VAI, SAI, IFI	OS, PFS
Fukushima et al. 2020 [26]	R	Japan	01/2018-02/2020	28	74 (70-82) <sup>b</sup>	19/9	UC	II	Pembrolizumab	6 (3-18) <sup>b</sup>	SMI	OS, PFS
Shimizu et al. 2020 [27]	R	Japan	12/2017-08/2019	27	73 (52-82) <sup>a</sup>	23/4	UC	II	Pembrolizumab	7 (1-20) <sup>a</sup>	PMI	OS, PFS

<sup>a</sup> medians with ranges; <sup>b</sup> median and interquartile range; <sup>c</sup> medians; <sup>d</sup> < 65/≥ 65; <sup>e</sup> < 75/≥ 75; R retrospective study; UC, urothelial carcinoma; RCC, renal cell carcinoma; PMI, psoas muscle index; VAI, visceral adiposity index; SAI, subcutaneous adiposity index; IAI, inter-muscular adiposity index; IFI, immune checkpoint inhibitor

The corrected Table 1:

**Table 1** Main characteristics of the studies included

Study	Study design	Study region	Study period	Sample size	Age	Male/female	Site	Treatment line	Treatment	Follow-up (months)	Body composition variables	Outcomes
Aslan et al. 2022 [19]	R	Turkey	10/2010–10/2021	52	30/22 <sup>d</sup>	38/14	RCC	II	Nivolumab	11.4 (0.7–63) <sup>a</sup>	SAI	OS, PFS
Fukata et al. 2022 [20]	R	Japan	02/2018–03/2021,	44	70 (54–80) <sup>a</sup>	30/14	UC	II	Pembrolizumab	13.2(1–40.8) <sup>a</sup>	SMI	PFS
Ged et al. 2022 [21]	R	USA	07/2011–04/2020	205	63 (40–90) <sup>a</sup>	152/53	RCC	I/II	ICIs	31.2 (1–77.8) <sup>a</sup>	SML, VAI, SAI	OS
Herrmann et al. 2022 [22]	R	France	2016–2020	46	66 (37–86) <sup>a</sup>	31/13	RCC	II	Nivolumab	16 <sup>c</sup>	SML	OS
Ueki et al. 2022 [23]	R	Japan	12/2016–10/2020	96	65/31 <sup>e</sup>	71/25	RCC	II	Nivolumab	9.7 (0.3–48.4) <sup>a</sup>	PMI, SMI	OS, PFS
Martini et al. 2021(RCC) [24]	R	USA	2015–2020	79	61.0 <sup>f</sup>	58/21	RCC	I/II	ICIs	–	SML, VAI, SAI, IAI	OS, PFS
Martini et al. 2021(UC) [25]	R	USA	2015–2020	70	69.5 <sup>f</sup>	49/21	UC	I/II	ICIs	20.1 <sup>c</sup>	SML, VAI, SAI, IFI	OS, PFS
Fukushima et al. 2020 [26]	R	Japan	01/2018–02/2020	28	74 (70–82) <sup>b</sup>	19/9	UC	II	Pembrolizumab	6 (3–18) <sup>b</sup>	SML	OS, PFS
Shimizu et al. 2020 [27]	R	Japan	12/2017–08/2019	27	73 (52–82) <sup>a</sup>	23/4	UC	II	Pembrolizumab	7 (1–20) <sup>a</sup>	PMI	OS, PFS
Takei et al. 2024 [28]	R	Japan	2019–2023	60	71 (63–75)	46/14	RCC	I/II	Ipilimumab+Nivolumab	15(1–52) <sup>a</sup>	SML, VAI, SAI	OS, PFS

<sup>a</sup> medians with ranges; <sup>b</sup> median and interquartile range; <sup>c</sup> medians; <sup>d</sup> < 65; <sup>e</sup> > 65; <sup>f</sup> < 75/≥ 75; R, retrospective study; UC, urothelial carcinoma; RCC, renal cell carcinoma; SML, skeletal muscle index; PMI, psoas muscle index; VAI, visceral adiposity index; SAI, subcutaneous adiposity index; IAI, inter-muscular adiposity index; IFI, immune checkpoint inhibitor

The original article [1] has been corrected.

Published online: 16 July 2024

**Reference**

1. Ma W, Shi Q, Zhang L, et al. Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies. *BMC Cancer*. 2024;24:830. <https://doi.org/10.1186/s12885-024-12579-x>.